当前位置:首页 >财报库 > 报告详情

吉利德科学Gilead Sciences(GILD)2023年ESG报告「NASDAQ」(英文版)(132页).pdf

上传人: Kell****reet 编号:653866 2025-05-20 132页 20.84MB

下载:

1、2023 E N VI R O N M E N TA L S O C I A L G OV E R N A N C E I M PAC T R E P O RTCREATINGREPORTINGINNOVATINGADVANCINGEMPOWERINGSUSTAININGCONTENTS 7/CREATING POSSIBLE 8/About Gilead 10/ESG at Gilead 16/INNOVATING SCIENTIFIC SOLUTIONS 18/Tailoring Science to Individual Needs 28/ADVANCING HEALTH EQUITY

2、AND ACCESS 30/Partnering to Provide Equitable Care 32/Scaling Equitable Solutions Through Health Grants 36/Fostering Clinical Trial Diversity 38/Reaching Patients Worldwide 47/Strengthening Sustainable Healthcare Delivery 51/EMPOWERING PEOPLE AND COMMUNITIES 53/Engaging and Developing Employees 64/C

3、ultivating an Inclusive Workplace 68/Tracking Our Workforce 71/Lifting Our Local Communities 76/SUSTAINING OUR SHARED PLANET 78/Strategizing Our Approach to Progress 79/Catalyzing a Multidimensional Carbon Reduction Strategy 85/Optimizing Water Use 87/Reducing Waste,Rethinking Materials 89/Greening

4、Our Labs 90/Sharing Sustainable Best Practices 94/REPORTING OUR PROGRESSON THE COVER:Darcie Green/Executive Director,Latinas Contra Cancer(Gilead grantee)32 0 2 3 E N V I R ON ME N TA L S O CIA L G OV E RN ANC E IM PAC T REPORTFORWARD-LOOKING STATEMENTSStatements in this 2023 Environmental Social Go

5、vernance Impact Report that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to

6、 differ materially.These risks and uncertainties are identified in Gileads disclosure documents filed with the U.S.Securities and Exchange Commission,and there may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements.The reader i

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要介绍了Gilead公司2023年的环境、社会和治理(ESG)影响报告。报告分为四个部分:创新科学解决方案、推进健康公平和获取、赋权人民和社区、维护我们共享的地球。 Gilead公司在HIV和乙型肝炎病毒(HBV)治疗方面做出了重大贡献,2023年提供了超过2000万次治疗。此外,自2013年以来,Gilead基于索福布韦的丙型肝炎病毒(HCV)治疗已使超过2600万人受益。 Gilead公司还致力于癌症治疗的研究,2020年Trodelvy®获得了美国食品和药物管理局(FDA)的加速批准,用于治疗某些转移性三阴性乳腺癌(mTNBC)患者。 在健康公平方面,Gilead公司通过与社区组织合作,推进健康公平,并资助了多个项目,包括HIV Age Positively®和Zeroing In™项目。 在环境可持续性方面,Gilead公司设定了雄心勃勃的气候目标,包括到2030年将温室气体排放量减少46%,并在水资源紧张的地区实现水资源平衡。 总的来说,Gilead公司在创新科学解决方案、推进健康公平和获取、赋权人民和社区、维护我们共享的地球等方面取得了显著的进步。
Gilead如何通过ESG原则创造更健康的世界? Gilead如何通过创新药物改善患者生活? Gilead如何在全球范围内提高HIV治疗的可及性?
客服
商务合作
小程序
服务号
折叠